GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kissei Pharmaceutical Co Ltd (TSE:4547) » Definitions » EV-to-EBIT

Kissei Pharmaceutical Co (TSE:4547) EV-to-EBIT : 6.65 (As of May. 13, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Kissei Pharmaceutical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kissei Pharmaceutical Co's Enterprise Value is 円96,201 Mil. Kissei Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円14,467 Mil. Therefore, Kissei Pharmaceutical Co's EV-to-EBIT for today is 6.65.

The historical rank and industry rank for Kissei Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:

TSE:4547' s EV-to-EBIT Range Over the Past 10 Years
Min: 3.57   Med: 7.78   Max: 17.84
Current: 6.65

During the past 13 years, the highest EV-to-EBIT of Kissei Pharmaceutical Co was 17.84. The lowest was 3.57. And the median was 7.78.

TSE:4547's EV-to-EBIT is ranked better than
86.06% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.91 vs TSE:4547: 6.65

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Kissei Pharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 was 円96,581 Mil. Kissei Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円14,467 Mil. Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 14.98%.


Kissei Pharmaceutical Co EV-to-EBIT Historical Data

The historical data trend for Kissei Pharmaceutical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kissei Pharmaceutical Co EV-to-EBIT Chart

Kissei Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.58 9.46 4.06 5.44 7.72

Kissei Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.44 5.46 6.56 6.11 -

Competitive Comparison of Kissei Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Kissei Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kissei Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kissei Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kissei Pharmaceutical Co's EV-to-EBIT falls into.



Kissei Pharmaceutical Co EV-to-EBIT Calculation

Kissei Pharmaceutical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=96201.158/14467
=6.65

Kissei Pharmaceutical Co's current Enterprise Value is 円96,201 Mil.
Kissei Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円14,467 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kissei Pharmaceutical Co  (TSE:4547) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=14467/96580.517
=14.98 %

Kissei Pharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 was 円96,581 Mil.
Kissei Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円14,467 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kissei Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Kissei Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Kissei Pharmaceutical Co (TSE:4547) Business Description

Traded in Other Exchanges
Address
19-48, Yoshino, Matsumoto City, Nagano, JPN, 399-8710
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kissei Pharmaceutical Co (TSE:4547) Headlines

No Headlines